Scientists just found a hidden reason
Stanford Medicine
A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.
More than one in four people with Type 2 diabetes use GLP-1
receptor agonists, a class of widely prescribed medications. However, new
research from Stanford Medicine and international collaborators suggests these
drugs may be less effective for some individuals due to genetic differences.
About 10% of the population carries certain genetic variants
linked to a newly identified phenomenon called GLP-1 resistance. In these
individuals, levels of the hormone GLP-1 (glucagon-like peptide-1), which helps
regulate blood sugar, are actually higher than normal but appear to be less
effective at doing their job.
It is still unclear whether these genetic variants influence
weight loss outcomes from GLP-1 drugs such as Ozempic and Wegovy, which are
increasingly used to treat obesity. These medications are typically prescribed
at higher doses for weight loss than for diabetes.
The study, published March 29 in Genome Medicine,
focused on how these drugs affect blood sugar. It represents a decade of work
involving experiments in both humans and mice, along with analysis of clinical
trial data.



.png)










